Millennium Management LLC Buys 308,753 Shares of Evolus, Inc. (NASDAQ:EOLS)

Millennium Management LLC grew its holdings in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 29.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,368,423 shares of the company's stock after buying an additional 308,753 shares during the period. Millennium Management LLC owned 2.16% of Evolus worth $15,107,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of EOLS. KBC Group NV bought a new stake in shares of Evolus during the 4th quarter valued at $49,000. IFP Advisors Inc boosted its holdings in shares of Evolus by 17,440.7% during the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock valued at $52,000 after buying an additional 4,709 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in shares of Evolus during the 4th quarter valued at $106,000. Quantbot Technologies LP bought a new stake in shares of Evolus during the 4th quarter valued at $118,000. Finally, Freestone Grove Partners LP bought a new stake in shares of Evolus during the 4th quarter valued at $140,000. Institutional investors own 90.69% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on EOLS shares. HC Wainwright reiterated a "buy" rating and issued a $27.00 price target on shares of Evolus in a research note on Thursday, April 10th. Barclays upped their target price on shares of Evolus from $22.00 to $25.00 and gave the company an "overweight" rating in a research note on Wednesday, March 5th. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price target on shares of Evolus in a research report on Thursday, May 8th. Finally, BTIG Research initiated coverage on Evolus in a report on Thursday, April 17th. They set a "buy" rating and a $21.00 price target for the company. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $23.75.

Insider Activity at Evolus

In other news, Director Karah Herdman Parschauer sold 12,888 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $12.99, for a total value of $167,415.12. Following the sale, the director now directly owns 32,183 shares in the company, valued at approximately $418,057.17. This represents a 28.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Sandra Beaver sold 8,996 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $119,286.96. Following the sale, the chief financial officer now directly owns 173,583 shares of the company's stock, valued at $2,301,710.58. This represents a 4.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 86,241 shares of company stock valued at $1,048,666. Insiders own 6.10% of the company's stock.

Evolus Price Performance

EOLS traded down $0.33 during trading on Wednesday, reaching $9.49. 718,569 shares of the company traded hands, compared to its average volume of 694,491. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. Evolus, Inc. has a 12-month low of $8.67 and a 12-month high of $17.82. The firm has a fifty day simple moving average of $10.82 and a 200 day simple moving average of $12.04. The company has a market cap of $611.55 million, a P/E ratio of -10.44 and a beta of 1.11.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.